MARCH7
E3 ubiquitin-protein ligase MARCH7
Protein Summary
E3 ubiquitin-protein ligase which may specifically enhance the E2 activity of HIP2. E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfer the ubiquitin to targeted substrates. MARCH7 is a member of the MARCH family of membrane-bound E3 ubiquitin ligases (EC 6.3.2.19). MARCH proteins add ubiquitin (see MIM 191339) to target lysines in substrate proteins, thereby signaling their vesicular transport between membrane compartments (Bartee et al., 2004 [PubMed 14722266]).[supplied by OMIM, Mar 2010]
- ENST00000259050
- ENSP00000259050
- ENSG00000136536
- ENST00000409175
- ENSP00000386830
- ENST00000409591
- ENSP00000387238
- AXOT
- RNF177
- AXO
- AXOT
- RNF177
- MARCH-VII
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
cellular component | 0.82 | ||
transcription factor perturbation | 0.74 | ||
histone modification site profile | 0.69 | ||
microRNA | 0.63 | ||
disease perturbation | 0.62 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 69.5 (req: < 5)
Gene RIFs: 9 (req: <= 3)
Antibodies: 243 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 69.5 (req: >= 5)
Gene RIFs: 9 (req: > 3)
Antibodies: 243 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 15
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0